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associated with Type 2 diabetes in Caucasian
population: a meta-analysis
Li-Li Chen, Song-Mei Han, Fei-Fei Tang and Qiang Li*Abstract
Background: Previous studies reported the relation between MTLRP genetic polymorphism and type 2 diabetes,
however, the conclusion were conflicting. In the present study, we performed a meta-analysis to reveal this association.
Methods: Literature retrieval, selection and assessment, data extraction, and meta-analyses were performed according
to the RevMan 5.0 guidelines. In the meta-analysis, we utilized random-effect model or fixed-effect model to pool the
Odds ratio (OR) according to the test of heterogeneity.
Results: A total of nine case–control studies included 4460 type 2 diabetes patients and 4114 healthy control
subjects were analyzed. We did not found association between the MTLRP polymorphism and type 2 diabetes risk
in the overall population (CC vs CA + AA: OR = 1.02; 95% CI: 0.89-1.17, P = 0.77; A vs C: OR = 1.02; 95% CI: 0.84-0.96,
P = 0.62). However, in subgroup analyses stratified by ethnicity, we found significant association of MTLRP
polymorphism with type 2 diabetes in Caucasians (CC vs CA + AA: OR = 1.27; 95% CI: 1.02-1.57, P = 0.03; A vs C:
OR = 0.74, 95% CI: 0.60–0.91, P = 0.005).
Conclusion: The MTLRP polymorphism was associated with type 2 diabetes in Caucasians.
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The prevalence of type 2 diabetes is rapidly increasing
and has become one of the most common chronic diseases
worldwide [1,2]. Since type 2 diabetes is associated with an
increased incidence of cardiovascular disease and long-
term mortality, it imposes a significant economic burden
on healthcare worldwide [3,4]. Recently, genetics were con-
sidered to be the main factor contributing to the develop-
ment and progression of type 2 diabetes [5,6]. Therefore,
the identification of genetic variants involved in individual
susceptibility to type 2 diabetes can assist our understand-
ing of the underlying disease process, and help to develop
novel therapies.
Ghrelin is a 28 amino acid peptide with an n-octanoylated
serine 3 residue primarily expressed in the X/A-like oxyn-
tic cells of the stomach but also in the hypothalamus and* Correspondence: qiang_li765@126.com
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unless otherwise stated.pancreas [7-10]. Ghrelin was discovered as the endogen-
ous ligand of the growth hormone secretagogue receptor
(GHSR). The peptide stimulates growth hormone release
and appetite [11,12]. Administration of ghrelin in rodents
induces weight gain by a reduction in fat utilization [13],
and ghrelin stimulates appetite and regulates the weight
balance through the GHSR by activation of neuropeptide
Y (NPY) and agouti related peptide (AGRP) containing
neurons in the hypothalamus [14,15]. MTLRP is a gene
coding Ghrelin peptide and has been considered as a can-
didate gene for type 2 diabetes. The human MTLRP gene
is located on chromosome 3 and consists of four exons
and three introns. Several single nucleotide polymor-
phisms (SNPs) have been described within this gene. One
missense polymorphism, 214C>A at codon 72 with Met
replacing Leu, is outside the region where the mature
ghrelin product is encoded and its functional significance
remains largely unknown. Recently, there were many gen-
etic studies reported the association between this poly-
morphism and type 2 diabetes. However, evidence fromtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow chart of selection of literatures.
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Although the previous meta-analysis performed by Liao
et al. in 2013 [16] has reported on the relation between
this polymorphism and type 2 diabetes, it involved less lit-
eratures and had lower power. Furthermore, three import-
ant studies [17-19] were not included in Liao et al.’s
studies. Therefore, for the present study, we have collected
almost all published case–control studies to perform an
update meta-analysis to further investigate the association
between this SNP and risk for type 2 diabetes.
Materials and methods
Literature collection and screening
We searched and identified literatures in PubMed, EMBASE,
ISI Web of Science, Wangfang in China and CNKI databases
using the terms “MTLRP ” or “ghrelin” or “preghrelin”
and “polymorphism” or “SNP” or “Leu72Met ” or “214C>A”
and “type 2 diabetes”.
Inclusion and exclusion criteria
The inclusion criteria was as follows: 1) the clinical re-
search of direct comparison of MTLRP polymorphism
between Type 2 diabetes and health control subjects
without any restriction on language or publication year;
2) Type 2 diabetes patients were diagnosed according to
WHO criteria or American Diabetes Association criteria
without any restriction on age or racial; 3) the design
was case–control study; and 4) genotypes were clearly
reported or could be calculated.
Literature quality assessment and data extraction
Two independent reviewers (LLC and SMH) carried out
the literature filtering and quality assessment. We excluded
literatures obviously does not meet the inclusion criteria
and duplicated publications. If inconsistencies existed, we
resolved it through discussion. The Cochrane Handbook
5.0 Quality evaluation criteria were utilized to evaluate
methodological quality of included studies. For each study,
the following characteristics were extracted: the first au-
thor’s last name, year of publication, country of origin,
the numbers and age of cases and controls.
Data analysis
We utilized RevMan 5.0 software which was provided by
the Cochrane Collaboration to perform the meta-analysis
and to merge the OR values. We directly used Q-test and
I2 test to examine the heterogeneity between each study.
The OR value was utilized to evaluate the relationship be-
tween the MTLRP polymorphism and Type 2 diabetes. By
heterogeneity test, if P > 0.05, we select the fixed effect
mode1, and if P <0.05, we select the random effect mode1
to merge OR. P <0.05 was considered as significant dif-
ference. Analysis of sensitivity includes the difference of
point estimation and confidence intervals of the combinedeffects value at a different model, to observe whether it
changes the result. To test the publication bias, we utilized
the RevMan 5.0 statistical software to make the funnel
plot.Results
Literature screening
As shown in Figure 1, there are 98 literatures preliminarily
detected, and 89 literatures were excluded due to duplicated
publication, not providing genotype data and non-clinical
based research literature. A total of 9 literatures were in-
cluded. These 9 studies [17-25] including 4460 patients
with type 2 diabetes and 4114 healthy control subjects
were included in this research.The characteristics of these studies
As shown in Table 1, in these 9 studies, there were 3
studies carried out in Caucasian population, and 6 studies
performed in Asian population. All these 9 studies provided
genotype data and all are in line with Hardy-Weinberg
equilibrium (HWE).The relation between MTLRP polymorphism and Type 2
diabetes
There was not significant heterogeneity between each
study (P = 0.15, I2 = 33%) in overall population (P = 0.15,
I2 = 33%) and in Caucasian population (P = 0.44, I2 = 0%).
Therefore, we utilized the fixed-effect model to merge
OR value. The meta-analysis results (Figures 2 and 3) sug-
gested that, in overall population, there are not significant
differences between Type 2 diabetes and healthy control
subjects in genotypes (CC vs CA +AA: OR = 1.02; 95% CI:
0.89-1.17, P = 0.77) (Figure 2A) or alleles (A vs C:
OR = 1.02; 95% CI: 0.84-0.96, P = 0.62) distribution
(Figure 3A). However, in Caucasian population, subjects
with A allele have decreased risk for Type 2 diabetes
(OR = 0.74, 95% CI: 0.60–0.91, P = 0.005) (Figures 2B
and 3B).
Table 1 The characteristics of included studies
Authors Publication year Country Ethnicity Case/control (n) Age HWE
Case Control
Larsen et al. [24] 2005 Denmark Caucasian 557/233 60 ± 11 52 ± 14 Yes
Kim et al. [23] 2006 Korea Asian 206/80 56.4 ± 10.1 54.9 ± 9.5 Yes
Choi et al. [22] 2006 Korea Asian 760 /641 59 ± 10 65 ± 4 Yes
Berthold et al. [20] 2009 Germany Caucasian 420/430 61 ± 12 63 ± 7 Yes
Garcia et al. [25] 2009 France Caucasian 610/820 60 52 Yes
Liu J, et al. [18] 2012a China Asian 864/877 53 ± 11 53 ± 12 Yes
Liu J, et al. [21] 2012b China Asian 744/1024 56 ± 8 54 ± 11 Yes
Xu et al. [19] 2008 China Asian 333/202 50 ± 8 49 ± 6 Yes
Zhang et al. [17] 2011 China Asian 138/113 54 ± 12 54 ± 15 Yes
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We deleted one single study from the overall pooled
analysis each time to check the influence of the removed
data set to the overall ORs. The pooled ORs and 95%
CIs were not significantly altered when any part of the
study was omitted, which indicated that any single study
had little impact on the overall ORs.
Publication bias analysis
We analyzed publication bias by use of Revman 5.2 soft-
ware, the funnel plot (Figure 4) shows the points evenly
distributed, symmetrical, and most of the points are
within the 95% confidence interval. It indicates there is
no publication bias, and the result of study is credible.Figure 2 Forest plot of MTLRP genetic polymorphism (214C>A) and T
horizontal lines correspond to the study-specific OR and 95% CI, resp
The diamond represents the pooled results of OR and 95% CI. (A: In total; BDiscussion
In the present study, we found an association of MTLRP
genetic polymorphism (214C>A) with Type 2 diabetes in
Caucasian population. However, we did not found this
association in Asian population.
Several previous studies suggested that MTLRP 214C>A
polymorphism was associated with the risk for type 2 dia-
betes. However, other case–control studies reported con-
flicting results. This may partly be due to a small sample
size in each of the published studies and ethnic difference.
Meta-analysis is a useful statistical method that combines
findings from independent studies. In the present study,
we found that, in Caucasians, the risk for type 2 diabetes
was decreased in subjects with C allele or CC genotype.ype 2 diabetes (CC genotype vs CA + AA genotype), the
ectively. The area of the squares reflects the study-specific weight.
: In Caucasian).
Figure 3 Forest plot of MTLRP genetic polymorphism (214C>A) and Type 2 diabetes (A allele vs C allele), the horizontal lines
correspond to the study-specific OR and 95% CI, respectively. The area of the squares reflects the study-specific weight. The diamond
represents the pooled results of OR and 95% CI. (A: In total; B: In Caucasian).
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reason for this discrepancy may be as follows: 1) there are
different genetic backgrounds between Caucasians and
Asian, which plays an important role; and 2) type 2 dia-
betes is a sophisticated disease which is affected by an
interaction between many factors, including environmen-
tal exposure, life style, socioeconomic status and individual
susceptibility. It is possible that individual susceptibility in
different ethnic group may be modified by environmental
exposure, life style and socioeconomic status in a different
way.
Further more, although we have found a positive associ-
ation of MTLRP polymorphism with Type 2 diabetes inFigure 4 Begg’s funnel plot for publication bias tests. Each
point represents a separate study for the indicated association. Log
or represents natural logarithm of OR. Vertical line represents the
mean effects size.Caucasian population, the total sample size of Caucasians
in this meta-analysis is still relatively small, which may
restrict the statistical power for achieving a definitive
conclusion. Therefore, case–control studies in larger
samples are needed to confirm this correlation found in
Caucasians.
In addition, the characteristic of meta-analysis is to
combine comparable studies to increase the sample size
and statistical power and draw a more compelling result.
However, meta-analysis confounds factors such as publi-
cation bias, method of sampling, different genetic back-
grounds of subjects, different protocols and quality of
analysis. In the present study, we did not found the publi-
cation bias, and the genotypes in all studies were detected
with genetic DNA from blood samples using PCR-RFLP
genotyping methods. All of the studies checked genotypes
for quality control. Genotype distribution of controls in all
studies was consistent with HWE.
Exploring heterogeneity is one of the important goals
of meta-analysis. In the present study no significant het-
erogeneity was found among the included studies. Sensi-
tivity analysis also showed that omission of any single
study did not have significant impact on the combined
ORs. This made the results of this meta-study more reli-
able to some extent.
However, there remained some limitations in this meta-
analysis. Although the genotyping methods used in all the
studies were the same, other clinical factors such as age,
sex and different treatment in each study might lead to
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the results of this meta-analysis would need further inves-
tigation. In addition, although we concluded that there is
no bias in our study by statistical analysis, in reality we all
know that the papers having negative results were prob-
ably published with more difficultly. Therefore, the inevit-
able publication bias may exist in the results.
Conclusion
Our study suggested that 214C>A polymorphism in the
MTLRP gene was associated with risk of Type 2 diabetes
in Caucasian population. Larger well-designed epidemio-
logical studies with ethnically diverse populations and func-
tional evaluations are warranted to confirm our findings.
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